Pawan Poddar, Arvinda Podila, Majed Abdul Basit Momin
{"title":"替格瑞洛诱导的急性孤立性血小板减少症。","authors":"Pawan Poddar, Arvinda Podila, Majed Abdul Basit Momin","doi":"10.4103/ijp.ijp_124_25","DOIUrl":null,"url":null,"abstract":"<p><p>Ticagrelor is an oral antiplatelet drug. The most common ticagrelor side effects include bleeding, dyspnea, bradycardia and in rare cases, microangiopathic hemolytic anemia. Isolated thrombocytopenia followed by a single-bolus dosage of ticagrelor is extremely uncommon. We encountered a 68-year-old male who had experienced rapid onset of chest pain and sweating for a day. The initial cardiac assessment suggested acute coronary syndrome and other laboratory tests, including a hemogram, were normal. The patient developed severe thrombocytopenia after receiving a loading dose of ticagrelor, despite the fact that no other thrombocytopenia-causing medicines were given to him. After discontinuing ticagrelor, the patient's platelet count gradually recovered with no need for additional transfusions or unnecessary investigations.</p>","PeriodicalId":49189,"journal":{"name":"the Indian Journal of Pharmacy","volume":"57 5","pages":"353-355"},"PeriodicalIF":1.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419566/pdf/","citationCount":"0","resultStr":"{\"title\":\"Ticagrelor-induced acute isolated thrombocytopenia.\",\"authors\":\"Pawan Poddar, Arvinda Podila, Majed Abdul Basit Momin\",\"doi\":\"10.4103/ijp.ijp_124_25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Ticagrelor is an oral antiplatelet drug. The most common ticagrelor side effects include bleeding, dyspnea, bradycardia and in rare cases, microangiopathic hemolytic anemia. Isolated thrombocytopenia followed by a single-bolus dosage of ticagrelor is extremely uncommon. We encountered a 68-year-old male who had experienced rapid onset of chest pain and sweating for a day. The initial cardiac assessment suggested acute coronary syndrome and other laboratory tests, including a hemogram, were normal. The patient developed severe thrombocytopenia after receiving a loading dose of ticagrelor, despite the fact that no other thrombocytopenia-causing medicines were given to him. After discontinuing ticagrelor, the patient's platelet count gradually recovered with no need for additional transfusions or unnecessary investigations.</p>\",\"PeriodicalId\":49189,\"journal\":{\"name\":\"the Indian Journal of Pharmacy\",\"volume\":\"57 5\",\"pages\":\"353-355\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12419566/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"the Indian Journal of Pharmacy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/ijp.ijp_124_25\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/22 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"the Indian Journal of Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/ijp.ijp_124_25","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Ticagrelor is an oral antiplatelet drug. The most common ticagrelor side effects include bleeding, dyspnea, bradycardia and in rare cases, microangiopathic hemolytic anemia. Isolated thrombocytopenia followed by a single-bolus dosage of ticagrelor is extremely uncommon. We encountered a 68-year-old male who had experienced rapid onset of chest pain and sweating for a day. The initial cardiac assessment suggested acute coronary syndrome and other laboratory tests, including a hemogram, were normal. The patient developed severe thrombocytopenia after receiving a loading dose of ticagrelor, despite the fact that no other thrombocytopenia-causing medicines were given to him. After discontinuing ticagrelor, the patient's platelet count gradually recovered with no need for additional transfusions or unnecessary investigations.
期刊介绍:
Indian Journal of Pharmacology accepts, in English, review articles, articles for educational forum, original research articles (full length and short communications), letter to editor, case reports and interesting fillers. Articles concerning all aspects of pharmacology will be considered. Articles of general interest (e.g. methods, therapeutics, medical education, interesting websites, new drug information and commentary on a recent topic) are also welcome.